Aldeyra Therapeutics, Inc.
ALDX
$1.91
$0.021.06%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 1.95M | 3.70M | 3.04M | 3.21M | 1.80M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 16.58M | 16.14M | 18.01M | 9.39M | 6.10M |
Operating Income | -16.58M | -16.14M | -18.01M | -9.39M | -6.10M |
Income Before Tax | -15.81M | -15.11M | -16.85M | -8.08M | -4.75M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -15.81M | -15.11M | -16.85M | -8.08M | -4.75M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.81M | -15.11M | -16.85M | -8.08M | -4.75M |
EBIT | -16.58M | -16.14M | -18.01M | -9.39M | -6.10M |
EBITDA | -16.51M | -16.07M | -17.95M | -9.33M | -6.03M |
EPS Basic | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 |
Normalized Basic EPS | -0.17 | -0.16 | -0.18 | -0.09 | -0.05 |
EPS Diluted | -0.27 | -0.25 | -0.28 | -0.14 | -0.08 |
Normalized Diluted EPS | -0.17 | -0.16 | -0.18 | -0.09 | -0.05 |
Average Basic Shares Outstanding | 59.58M | 59.53M | 59.41M | 59.41M | 59.20M |
Average Diluted Shares Outstanding | 59.58M | 59.53M | 59.41M | 59.41M | 59.20M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |